Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634038 | 1.00 | EED (0.34) | EEDSUZ12EZH2EGFRMAPT | |
| SCHEMBL25208990 | 0.89 | HTR2C (0.36) | EGFRMAPTMAOBLMNAHTT | |
| SCHEMBL20741822 | 0.78 | HTR2A (0.43) | EEDSUZ12EZH2MAPTMAOB | |
| SCHEMBL30949613 | 0.78 | HTR2A (0.43) | EEDSUZ12EZH2MAPTMAOB | |
| SCHEMBL30754266 | 0.76 | MTNR1B (0.35) | EGFRMAPTMAOBLMNAHTT | |
| SCHEMBL20744138 | 0.76 | HTR2C (0.35) | MAPTLMNAHTTBLMMTNR1B | |
| SCHEMBL30684141 | 0.76 | HTR2C (0.35) | MAPTLMNAHTTBLMMTNR1B | |
| SCHEMBL1764937 | 0.76 | MTNR1B (0.35) | EGFRMAPTMAOBLMNAHTT | |
| SCHEMBL16190012 | 0.76 | HTR2C (0.35) | MAPTHTR2AHTR2CHTR2BKIF11 | |
| SCHEMBL14720202 | 0.74 | ABCC9 (0.36) | MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12162864-B2 | Condensed-cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-10 | — | — | US | disclosed |
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-02-29 | — | — | US | disclosed |
| EP-4273149-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022146027-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-07 | — | — | WO | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020067457-A1 | CONDENSED-CYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2014169845-A2 | 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF | 四川海思科制药有限公司 (CN) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EED 764/4885SUZ12 511/4885EZH2 1494/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EED 1061/4885SUZ12 1184/4885EZH2 1530/4885 |
| US-12162864-B2 | Condensed-cyclic compound | SLC10A2, VIP, AVPR2 | EED 963/4885SUZ12 653/4885EZH2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.